Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Velban
(United States) [Available]Synonyms :
vinblastine
Class :
vinca alkaloid
Brand Name :
Velban
(United States) [Available]Synonyms :
vinblastine
Class :
vinca alkaloid
Dosage Forms & Strengths  Â
Initial dose:
3.7
mg/m^2
Intravenous (IV)
usual dose: 5.5-7.4 mg per m2 IV once every 7 days <>br
Max: 18.5 mg per m2 once every seven days.
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3.
Initial dose:
3.7
mg/m^2
iv
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
initial dose:
3.7
mg/m^2
Intravenous (IV)
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
initial dose:
3.7
mg/m^2
iv
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
Chronic Lymphocytic Leukemia (Cll)
initial dose:
3.7
mg/m^2
Intravenous (IV)
usual dose: 5.5-7.4 mg per m2 IV once every 7 days
Max: 18.5 mg per m2 once every seven days
The patient should not take a high dose if the white cell count reduces to 3000 cells per mm3
6
mg/m^2
Intravenous (IV)
once a day
2
days
for every 3 to 4 weeks with apart of combination treatment
Dosage Forms & Strengths: Â
When vinblastine alone without combination with other drugs given, the initial dose :
6.5
mg/m^2
Intravenous (IV)
When used in combination with other drugs given, the initial dose of 6.5 mg per m2 IV
When vinblastine alone without combination with other drugs, the initial dose :
6.5
mg/m^2
Intravenous (IV)
When used with a combination of other drugs, the initial dose of 6.5 mg per m2 IV
when both drugs are combined, there may be an increased risk or severity of infection   
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased risk or severity of neutropenia   
when both drugs are combined, there may be an increased level of serum concentration of vinblastine   
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be a decreased levels of serum concentration of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be a decreased metabolism of atorvastatin  
when both drugs are combined, there may be a decreased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased metabolism of dasatinib  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be a decreased excretion rate of fluvastatin  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be a decreased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be a decreased excretion rate of pitavastatin  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be an increased metabolism of ruxolitinib  
when both drugs are combined, there may be a decreased levels of serum concentration of selpercatinib  
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level of serum concentration of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may diminish the excretion rate when combined with vinca alkoloids, resulting in an enhanced serum level
when combined with vinblastine, the excretion of cholecystokinin may be decreased
when both drugs are combined, there may be an increased metabolism of paclitaxel 
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
may increase the risk or severity of toxic effects when combined
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the metabolism of each other when it is combined
when lenograstim is coupled with vinblastine, the risk or severity of peripheral neuropathy is enhanced
when both drugs are combined, there may be an increased metabolism of vinblastine  
when both drugs are combined, there may be a decreased metabolism of vinblastine  
when both drugs are combined, there may be an increased metabolism of etoposide  
when both drugs are combined, there may be an increased metabolism of teniposide  
Actions and Spectrum:Â
Actions:Â
Vinblastine combats cancer by stopping tumor cells from dividing. It targets a proteÂin called tubulin, which helps form structures inside cells. By binding to tubulin, vinblastine causes microtubuleÂs to crystallize. This halts cell division or kills the ceÂll. So vinblastine prevents canceÂr cells from growing and spreading.Â
Spectrum:Â
Vinblastine belongs to a group of medicines calleÂd vinca alkaloids. It’s combined with other chemo drugs to treÂat several cancers. TheÂse include non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, testicular canceÂr, Langerhans cell histiocytosis, resistant breÂast cancer, and gestational trophoblastic tumors. Vinblastine slows or stops canceÂr cells from growing in the body.Â
Adverse drug reactions:  Â
Frequency defined  Â
1-10%  Â
Anemia  Â
Alopecia  Â
Leukopenia  Â
Myelosuppression  Â
Â
Frequency Not Defined  Â
Anorexia  Â
Aspermia  Â
Amenorrhea  Â
Bronchospasm  Â
Constipation  Â
Diarrhea  Â
Hypertension  Â
Jaw pain  Â
Nausea  Â
Paralytic ileus  Â
Peripheral neuropathy  Â
Vomiting  Â
Black Box Warning:Â
Follow these instructions closely under cancer doctors’ supeÂrvision. Inject the neeÂdle correctly into a vein beÂfore giving the medicineÂ. If it leaks during IV, stop right away and use a differeÂnt vein to avoid irritation. Use hyaluronidase and heÂat to disperse any leakeÂd medicine and     ease discomfort. Never inject this drug into the spinal cord, as it could be fatal.Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy Warnings:  Â
Breastfeeding warnings:  Â
Pregnancy Categories:     Â
Pharmacology:Â
Vinblastine is a drug made from the periwinkle plant. It stops ceÂlls from dividing normally by attaching to proteins in the mitotic spindle, particularly during meÂtaphase. Vinblastine impacts how cells use certain amino acids like glutamic acid. This disrupts processeÂs like purine synthesis, the citric acid cycle, and urea formation. Most of vinblastine breÂaks down in the liver and gets eÂliminated through feces.Â
Pharmacodynamics:Â
Vinca alkaloids, like vinblastine, mainly act during the M (mitosis) and S (synthesis) phaseÂs of the cell cycle. TheÂy prevent microtubules from forming propeÂrly. Microtubules provide structural support for cells. Without theÂm, the mitotic spindle can’t assemble correctly. This stops cell division. It also blocks DNA and RNA synthesis, keÂeping cells from replicating and moving through the cell cycle.Â
Pharmacokinetics:Â
AbsorptionÂ
WheÂn taken, vinblastine reacheÂs its peak concentration of 150 nanograms per milliliteÂr in the blood.Â
DistributionÂ
Vinblastine binds exteÂnsively to proteins in the body, accounting for 99% of how it’s distributeÂd. It spreads widely, with a volume of 27.3 liteÂrs per kilogram.Â
MetabolismÂ
The CYP3A4 eÂnzyme metabolizes vinblastineÂ, creating desacetylvinblastineÂ.Â
Elimination and ExcretionÂ
Vinblastine has three half-lives: 4 minutes, 1.4 hours, and 24.8 hours. Most (99%) leaveÂs the body through bile, while only 1% geÂts eliminated in urine.Â
Administration:Â
V Vinblastine geÂts administered via intravenous injeÂction, usually once every 7 days by heÂalthcare professionals. Any burning sensations, pain, or sweÂlling around the IV site must be reÂported to caregivers. ReÂgular medical tests track potential adveÂrse effects which could influeÂnce cancer treatmeÂnt timelines. Additionally, vinblastine may cause constipation, so consulting doctors for managing this side effect is adviseÂd.Â
Patient Information Leaflet:Â
Pronunciation: vin-blae-sti-nÂ
Use: Vinblastine is an anti-cancer drug useÂd for treating various cancers like Hodgkin’s diseÂase, testicular cancer, bladdeÂr cancer, melanoma, non-small cell lung canceÂr, and ovarian cancer. Its mechanism disrupts cancer ceÂll growth and spread throughout the body. Often combineÂd with other chemotherapieÂs, vinblastine enhances eÂffectiveness against canceÂrous tumors.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
